Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Assets (2016 - 2025)

Historic Current Assets for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $216.1 million.

  • Abeona Therapeutics' Current Assets rose 9184.78% to $216.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.1 million, marking a year-over-year increase of 9184.78%. This contributed to the annual value of $100.9 million for FY2024, which is 8094.44% up from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Current Assets is $216.1 million, which was up 9184.78% from $232.3 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Current Assets ranged from a high of $232.3 million in Q2 2025 and a low of $25.5 million during Q3 2022
  • Its 5-year average for Current Assets is $83.3 million, with a median of $66.7 million in 2024.
  • Its Current Assets has fluctuated over the past 5 years, first plummeted by 6245.2% in 2022, then skyrocketed by 18589.85% in 2024.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Current Assets stood at $56.3 million in 2021, then decreased by 5.67% to $53.1 million in 2022, then rose by 4.97% to $55.7 million in 2023, then skyrocketed by 80.94% to $100.9 million in 2024, then surged by 114.3% to $216.1 million in 2025.
  • Its last three reported values are $216.1 million in Q3 2025, $232.3 million for Q2 2025, and $88.1 million during Q1 2025.